Accès ouvert
2026
article
OpenAlex
Sinthujah Vigneswaran, Inge M.W. Verberk, Lynn Boonkamp, Lisanne in ‘t Veld et autres
Importance: Blood-based biomarkers (BBM) provide minimally invasive, scalable, lower-cost tools for identifying neurodegenerative diseases, but prospective data on their clinical validity in memory clinic settings are limited. Objective: To evaluate how a tailored plasma BBM panel (phosphorylated tau 181 [pTau181], glial fibrillary …
nl, se, us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Sinthujah Vigneswaran, Inge M.W. Verberk, Rebecca Z. Rousset, Mariam Gouda et autres
Accurate plasma biomarker interpretation is essential for diagnosing Alzheimer’s disease (AD). This study evaluated how patient factors influence the association between plasma biomarkers and amyloid status in a memory clinic population. A cross-sectional study of 1199 participants from the Amsterdam Dementia Cohort …
nl, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Sinthujah Vigneswaran, Inge M.W. Verberk, Lynn Boonkamp, Lisanne in ‘t Veld et autres
BACKGROUND: Blood-based biomarkers (BBM) are emerging as minimally invasive, scalable and relatively low-cost options for discriminating different neurodegenerative diseases. Before implementation in clinical practice, it is important to determine their real-world clinical validity in patients presenting at memory clinics. To prospectively evaluate …
nl, se, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Michelle C. Barboure, Inge M.W. Verberk, Sinthujah Vigneswaran, Frederik Barkhof et autres
Abstract Background Plasma neurofilament light (NfL) is increasingly used as a general marker for neurodegeneration in memory clinics to aid differential diagnosis. However, interpreting its levels in the presence of vascular pathology remains unclear. We investigated the individual and combined effects of …
nl
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Inge M.W. Verberk, Michelle C. Barboure, Sinthujah Vigneswaran, Lynn Boonkamp et autres
Abstract Background Patients referred to specialized memory clinics present with different symptoms and etiologies. A blood test could streamline establishing etiological diagnoses. Given the diversity in patients seen at memory clinics, relying on a single marker, e.g. phosphorylated tau217 (pTau217), is insufficient. …
nl, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Bjørn‐Eivind Kirsebom, Fernando González‐Ortiz, Sinthujah Vigneswaran, Geir Bråthen et autres
INTRODUCTION: Heterogeneity of clinical progression in Alzheimer's disease (AD) complicates the assessment of disease progression and treatment effects in trials. This study evaluates the potential of plasma phosphorylated tau-217 (p-tau217) to capture this heterogeneity. METHODS: We used k-means clustering to analyze cognitive …
no, se, nl, gb, cn, fr
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Sinthujah Vigneswaran, Inge M.W. Verberk, Mariam Gouda, Elsmarieke van de Giessen et autres
Abstract Background Blood‐based biomarkers (BBM) for Alzheimer’s disease (AD) may be able to identify individuals eligible for emerging anti‐amyloid treatments (DMT). We aimed to evaluate how to use BBM as (pre‐) selection tools for DMTs by simulating different triaging scenarios in a …
nl, us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Sinthujah Vigneswaran, Inge M.W. Verberk, Lynn Boonkamp, Rebecca Z. Rousset et autres
Abstract Background Blood‐based biomarkers (BBM) are emerging as minimally invasive, scalable and relatively low‐cost options for discriminating different neurodegenerative diseases. Before implementation in clinical practice can take place, it is important to determine their real‐world clinical validity in patients presenting at a …
nl, se, us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Aniek M. van Gils, Antti J. Tolonen, Argonde C. van Harten, Sinthujah Vigneswaran et autres
BACKGROUND: The increasing prevalence of dementia and the introduction of disease-modifying therapies (DMTs) highlight the need for efficient diagnostic pathways in memory clinics. We present a data-driven approach to efficiently guide stepwise diagnostic testing for three clinical scenarios: 1) syndrome diagnosis, 2) …
nl, gb, se, fi, dk, it, no
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Sinthujah Vigneswaran, Inge M.W. Verberk, Mariam Gouda, Calvin Trieu et autres
Abstract Background Recent evidence suggests high potential for implementation of plasma biomarkers for Alzheimer’s disease(AD) such as amyloid‐beta42/40(Aβ42/40)‐ratio, tau‐phosphorylated‐at‐threonine‐181(P‐tau181), neurofilament‐light‐chain(NfL) and glial‐fibrillary‐acidic‐protein(GFAP). However, it is crucial to understand which factors could affect the diagnostic value of plasma biomarkers before they are implemented …
nl, us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Thomas Claessen, Sinthujah Vigneswaran, Inge M.W. Verberk, Anouk den Braber et autres
Abstract Background With the advent of disease‐modifying therapies, the need for accurate and cost‐effective diagnosis of Alzheimer’s disease (AD) is high. As the first step in the patient journey, the general practitioner plays an essential role in the diagnostic process. Accurately diagnosing …
nl, us
(code pays fourni par la source)